Ranbaxy wins one Atorvastatin patent in NorwayOur Web Bureau / Mumbai November 10, 2005Ranbaxy Laboratories, in a release posted on the company website, said a Norwegian court today handed down its decision in the company's case against Pfizer involving patents on Atorvastatin in Norway. "Atorvastatin is a cholesterol-lowering drug, which is marketed by Pfizer as Lipitor," the release said.The Norwegian court agreed with Ranbaxy by finding non-infringement of one key Pfizer Norwegian process patent. "At the same time, Ranbaxy
